DLL3-Targeted Immunotherapy Candidates Pipeline Review

Target: Delta-like canonical Notch ligand 3; DLL3; delta-like ligand 3

Product Category: Antibody; Cells

This product provides basic information on immunotherapy candidates in research and development targeting DLL3.

This product consists of:

• Competitors described in a tabular format covering drug code/INN, target(s)/MoA, class of compound, product category, indication(s) & R&D stage.
• Project History with links to source of information (press release, homepage, abstracts, presentations, annual reports etc).
• One-month online access to La Merie Publishing’s database for immunotherapy candidates targeting DLL3 (prerequisite: access to internet).

This product is delivered on the very same day of purchase by e-mail containing competitor and project history reports in pdf format and database credentials. Reports are prepared on the same day.

Delta-like canonical Notch ligand 3 (DLL3) is minimally expressed in normal tissue but expressed in 80-85% of (small cell lung cancer) SCLC tumors, and approximately 77% of neuroendocrine carcinomas (NECs)1 making DLL3 an ideal therapeutic target for these two indications of high unmet medical need.

Upregulated DLL3 functions as a Notch ligand and has been a target for cancer therapy. DLL3 is fundamental in the downstream cellular signaling for proliferation and apoptosis. DLL3 is an atypical member of the Notch receptor ligand family that is able to inhibit activation of the Notch receptors. DLL3 contains different functional domains (such as a Delta-Serrate-Lag2 [DSL] domain, epidermal growth factor [EGF] repeats, and a transmembrane domain). Aberrant DLL3 expression has been found in neuroendocrine cancers and also high-grade serous ovarian cancer.

SCLC is an aggressive neuroendocrine tumor; response to initial chemotherapy and radiotherapy is often followed by recurrence, rapid progression, and resistance to current therapies. New data show that >75% of castration-resistant small-cell neuroendocrine prostate cancers (CRPC-NE) express the Notch ligand delta-like protein 3 (DLL3). None of the benign and only 0.52% of localized prostate cancer samples were DLL3⁺. By contrast, 12.5% of CRPC adenocarcinomas and 76.6% of CRPC-NE expressed DLL3, and 10.37% and 63.95% of cells in these samples were DLL3⁺, respectively.